InvestorsHub Logo
Followers 62
Posts 1712
Boards Moderated 0
Alias Born 08/08/2005

Re: nuke661 post# 104752

Sunday, 12/16/2012 1:08:26 PM

Sunday, December 16, 2012 1:08:26 PM

Post# of 345995
Nuke, I was fishing around a bit more looking through news coverage. The phase 3 NP+G pancreatic trial is still under wraps, but thestreet.com was "suggesting" a survival number of 8 months. They said: "Investors are likely to view a survival benefit of 8 months for Abraxane/gemcitabine compared to 6 months for gemcitabine alone as a very positive result."

http://www.thestreet.com/story/11763237/1/celgene-abraxane-boosts-pancreatic-cancer-survival.html

IMO

sunstar
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent CDMO News